Skip to content
naulon

Not checkedNot checked for notices yet.

Alternatives to Acellular Dermal Matrix in Breast Reconstruction: Outcomes from Dermal Autograft Assisted Tissue Expander Breast Reconstruction in 104 Consecutive Patients

Brian D. Rinker, MD

Plastic and Reconstructive Surgery, Global Open · 2020

doi:10.1097/01.gox.0000720332.45888.3d (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

PURPOSE: Acellular dermal matrices (ADMs) have many benefits when used in implant-based breast reconstruction, but they add cost to the procedure and may increase complications. In addition, many patients prefer to avoid human-based products if there is an autologous option. For this reason, surgeons have sought viable alternatives to ADM in breast reconstruction. Dermal autografts can be harvested at the time of mastectomy and represent a useful, autologous alternative to ADMs. METHODS: One hundred four consecutive patients (171 breasts) underwent breast reconstruction using tissue expanders and dermal autograft over a 7-year period. Age ranged from 32 to 73 years (median, 53 years). Autografts were harvested from either the lower abdomen (n = 86) or the inferior breast (n = 18). Dermal autografts were used to cover the inferior pole of the tissue expander at the time of expander placement. Demographic data, clinical history, and harvest time were recorded. The initial fill volume, number of expansions, cost, and complications were compared to ADM-assisted reconstruction. Breast-Q surveys were mailed to all patients, and satisfaction ratings were compared with historical values of patients undergoing ADM-assisted breast reconstruction. A cost analysis was performed of dermal autograft assisted reconstruction, and this was compared with historical values for ADM-assisted reconstruction. RESULTS: Follow-up ranged from 9 months to 7 years (mean, 31 months). Twenty-five patients were smokers. Mean BMI was 30.5 (range, 19.1–48.8). Thirty-six patients received chemotherapy between reconstructive stages, 7 required radiation. The mean time of autograft harvest was 27 minutes; however, there was no difference in mean operative times between the ADM and autograft groups. The mean initial fill was 151 ml, and the average number of expansions was 4.2. There were 3 infections resulting in implant loss (3%). There were 14 minor complications (13%). Mild capsular contracture was observed in 3 patients, and no patients underwent reoperation for capsular contracture. Initial expander fill, number of expansions, and complication rate were equivalent to historical values for ADM-assisted breast reconstruction. The mean per patient cost savings for dermal autograft versus ADM-assisted reconstruction was 3,600 USD for unilateral and 7,639 USD for bilateral reconstructions. Survey data (response 30%) showed no statistically significant difference in any Breast-Q category between the ADM and the dermal autograft groups. CONCLUSIONS: The use of dermal autograft in tissue expander breast reconstruction offers the advantages of ADM at a lower cost. Dermal autograft-assisted breast reconstruction did not differ significantly from historical values for ADM regarding operative time, complication profile, capsular contracture, or patient-reported outcomes. However, cost was significantly lower in the dermal autograft group. Dermal autograft-assisted implant reconstruction should be considered in patients undergoing breast reconstruction, especially in patients who wish to avoid human-based products.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.